Your browser is no longer supported. Please, upgrade your browser.
CRMD [NASD]
CorMedix Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own1.20% Shs Outstand32.42M Perf Week-6.09%
Market Cap282.38M Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float31.48M Perf Month-16.01%
Income-22.00M PEG- EPS next Q-0.18 Inst Own23.20% Short Float8.23% Perf Quarter-44.07%
Sales0.20M P/S1411.88 EPS this Y57.20% Inst Trans-6.33% Short Ratio2.55 Perf Half Y43.88%
Book/sh1.36 P/B5.79 EPS next Y42.70% ROA-62.50% Target Price- Perf Year108.20%
Cash/sh1.29 P/C6.10 EPS next 5Y- ROE-74.20% 52W Range3.47 - 18.80 Perf YTD5.92%
Dividend- P/FCF- EPS past 5Y23.30% ROI-49.90% 52W High-58.67% Beta2.34
Dividend %- Quick Ratio11.50 Sales past 5Y2.60% Gross Margin14.40% 52W Low123.92% ATR0.55
Employees35 Current Ratio11.60 Sales Q/Q124.90% Oper. Margin- RSI (14)39.99 Volatility6.31% 7.17%
OptionableYes Debt/Eq0.00 EPS Q/Q9.10% Profit Margin- Rel Volume0.26 Prev Close7.87
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume1.02M Price7.77
Recom2.00 SMA20-5.20% SMA50-10.20% SMA2000.84% Volume89,186 Change-1.27%
Feb-17-21Initiated Needham Buy $31
Sep-29-20Initiated JMP Securities Mkt Outperform $22
Sep-21-20Initiated Truist Buy $20
Dec-18-19Initiated B. Riley FBR Buy $48
Mar-26-19Reiterated H.C. Wainwright Buy $3 → $15
Dec-06-18Initiated ROTH Capital Buy $6
Sep-25-17Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17Reiterated Rodman & Renshaw Buy $6 → $5
Nov-11-16Reiterated FBR & Co. Outperform $6 → $4
Mar-17-16Reiterated FBR Capital Outperform $7 → $6
Mar-03-16Initiated FBR Capital Outperform $7
Nov-16-15Reiterated ROTH Capital Neutral $2.75 → $2.50
Oct-29-15Reiterated ROTH Capital Neutral $4.50 → $2.75
May-06-15Downgrade ROTH Capital Buy → Neutral $2.50 → $7.50
Dec-08-14Reiterated ROTH Capital Buy $3 → $2.50
Oct-03-11Downgrade Maxim Group Buy → Hold
May-13-21 08:30AM  
May-05-21 08:00AM  
May-03-21 03:01PM  
Apr-28-21 08:30AM  
Apr-14-21 09:00AM  
Apr-07-21 08:30AM  
Mar-30-21 04:05PM  
Mar-25-21 10:35PM  
Mar-24-21 03:00AM  
Mar-23-21 08:30AM  
Mar-21-21 09:57PM  
Mar-18-21 04:48PM  
Mar-16-21 10:30PM  
Mar-15-21 08:30AM  
Mar-14-21 09:36PM  
Mar-12-21 05:35AM  
Mar-11-21 08:30AM  
Mar-09-21 10:24PM  
Mar-08-21 05:00PM  
12:30PM  
Mar-07-21 06:28PM  
Mar-04-21 11:00AM  
Mar-03-21 03:01PM  
Mar-01-21 08:55AM  
08:30AM  
Feb-17-21 04:15PM  
Feb-06-21 02:57AM  
Feb-02-21 08:05AM  
Jan-21-21 08:30AM  
Dec-01-20 12:21PM  
Nov-30-20 12:00PM  
Nov-24-20 12:00PM  
Nov-18-20 08:30AM  
Nov-08-20 08:47AM  
Nov-05-20 06:55PM  
04:05PM  
02:30PM  
Nov-02-20 08:30AM  
Oct-29-20 08:30AM  
Oct-08-20 09:00AM  
Sep-17-20 08:30AM  
Sep-09-20 08:30AM  
Sep-04-20 11:28AM  
Aug-31-20 07:47AM  
Aug-19-20 08:46AM  
Aug-10-20 05:35PM  
04:05PM  
Aug-07-20 11:10AM  
Aug-03-20 04:05PM  
Jul-27-20 04:05PM  
Jul-09-20 08:58AM  
Jul-08-20 08:30AM  
Jun-09-20 09:38AM  
May-27-20 11:41AM  
May-21-20 12:00PM  
May-17-20 08:48AM  
May-11-20 07:35PM  
04:10PM  
08:30AM  
May-06-20 08:30AM  
May-04-20 09:00AM  
Apr-23-20 08:15AM  
Apr-22-20 11:50AM  
08:00AM  
Apr-14-20 11:52AM  
Mar-31-20 07:52PM  
Mar-20-20 06:32AM  
Mar-19-20 10:40AM  
07:19AM  
Mar-16-20 05:55PM  
04:05PM  
02:30PM  
Mar-06-20 08:15AM  
Mar-05-20 12:30PM  
Feb-03-20 04:19PM  
08:15AM  
06:58AM  
Dec-20-19 10:56AM  
06:00AM  
Dec-08-19 08:44AM  
Dec-04-19 10:39PM  
Nov-14-19 05:35PM  
04:05PM  
Nov-07-19 08:00AM  
Nov-06-19 10:30AM  
08:15AM  
Oct-24-19 07:55AM  
Oct-16-19 08:15AM  
Sep-26-19 04:30PM  
08:15AM  
Sep-24-19 07:14PM  
Sep-18-19 10:17AM  
Sep-03-19 04:30PM  
Aug-20-19 02:11AM  
Aug-14-19 07:21PM  
Aug-13-19 05:45PM  
04:05PM  
01:47PM  
Aug-06-19 10:30AM  
Aug-01-19 08:30AM  
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lefkowitz Steven WDirectorSep 04Buy3.995,71522,81660,498Sep 09 08:47 AM
David Matthew TChief Financial OfficerSep 03Buy4.071,1504,6801,150Sep 08 08:38 AM
Kaplan MyronDirectorSep 02Buy4.2715,30065,359150,034Sep 04 08:25 AM
Khan MehmoodDirectorAug 19Buy4.9017,83787,472178,767Aug 20 05:53 PM
Khan MehmoodDirectorAug 18Buy4.8027,913133,878160,930Aug 20 05:53 PM
ARMSTRONG JR. JOHN L.Exec VP of Tech OperationsAug 14Buy4.2227,500116,11096,878Aug 17 08:06 PM
Mounts PhoebeGeneral CounselAug 13Buy4.032,52510,1767,200Aug 17 07:08 PM
Kaplan MyronDirectorAug 13Buy4.0815,00061,160134,734Aug 17 07:02 PM
Baluch KhosoChief Executive OfficerAug 13Buy4.144,83019,98560,905Aug 17 06:45 PM
DUNTON ALAN WDirectorAug 12Buy3.955,00019,7506,250Aug 14 05:29 PM
Kaplan MyronDirectorMay 15Buy3.8510,00038,500119,734May 18 04:20 PM